LGG
MRK icon

Luts & Greenleigh Group’s Merck MRK Stock Holding History

Luts & Greenleigh Group’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$611K Buy
4,755
+113
+2% +$13.2K 0.46% 45
2026
Q1 		$558K Buy
4,642
+11
+0.2% +$1.27K 0.44% 41
2025
Q4 		$488K Sell
4,631
-79
-2% -$7.42K 0.41% 45
2025
Q3 		$395K Buy
4,710
+2
+0% +$165 0.35% 52
2025
Q2 		$373K Buy
4,708
+171
+4% +$13.6K 0.36% 52
2025
Q1 		$407K Sell
4,537
-327
-7% -$30.5K 0.4% 48
2024
Q4 		$484K Buy
4,864
+421
+9% +$43.4K 0.48% 43
2024
Q3 		$504K Sell
4,443
-41
-0.9% -$4.87K 0.48% 43
2024
Q2 		$555K Buy
+4,484
New +$578K 0.58% 35
2023
Q4 		$597K Buy
5,472
+40
+0.7% +$4.15K 0.75% 29
2023
Q3 		$559K Sell
5,432
-194
-3% -$20.9K 0.69% 32
2023
Q2 		$649K Buy
5,626
+152
+3% +$17.3K 0.8% 30
2023
Q1 		$582K Buy
5,474
+47
+0.9% +$5.07K 0.74% 28
2022
Q4 		$602K Buy
+5,427
New +$555K 0.76% 25

Other funds holding MRK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Luts & Greenleigh Group's MRK Position: Q2 2026 in Review

Luts & Greenleigh Group increased its Merck (MRK) stake by 2.4% in Q2 2026, buying an estimated $13.2K and bringing the position to 4,755 shares worth $611K. The position accounts for 0.46% of the portfolio, ranked #45.

Luts & Greenleigh Group first reported a position in MRK in Q4 2022 and has held it in 14 quarters since. The position peaked at $649K in Q2 2023. 3,833 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Luts & Greenleigh Group held 4,755 shares of Merck worth $611K as of Q2 2026.
  • Luts & Greenleigh Group bought 113 Merck shares in Q2 2026, an estimated $13.2K.
  • Merck made up 0.46% of Luts & Greenleigh Group's portfolio in Q2 2026, its #45 holding.
  • Luts & Greenleigh Group first reported a position in Merck in Q4 2022 and has held it in 14 quarters since.
  • Luts & Greenleigh Group's Merck position peaked at $649K in Q2 2023.
  • 3,833 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Luts & Greenleigh Group's 13F filing for Q2 2026, filed 7 Aug 2026.